If anyone here has any further doubts that the ATM technology will also be used for degenerative and regenerative?
Well here is definitive proof and it has been on the Novogen website all along!
http://www.novogen.com/pdf/threeMinuteOverview.pdf
Novogen 3 minute update
Novogen is an Australian-US biotechnology company listed on both the Australian Securities Exchange (NRT) and NASDAQ (NVGN).
Novogen believes it has the potential to bring a new and considerably more effective way of thinking to the management of many of our community’s debilitating diseases.
Novogen owns two proprietary drug technology platforms that are first-in-class and which the Company believes will be the foundation that will enable us to grow into a major global biotechnology company.
Both technologies target essential functions that lie at the heart of cells behaving abnormally. These essential functions are present across a wide range of degenerative diseases, including cancer, neurodegenerative, musculodegenerative, metabolic disorders and autoimmune diseases.
These are entirely novel drug targets that Novogen believes addressing them will revolutionize the treatment of many of the common diseases affecting our community and for which no curative treatments currently exist.
“We are building a global biotechnology business around two first-in-class drug technology platforms that have potential reach across many of mankind’s most lethal and debilitating degenerative diseases.”
But wait, the best is yet to come!
Degenerative Diseases
The Company’s two drug technology platforms are being applied also to a variety of non-oncology degenerative disease applications.
In the case of the SBP platform, we are exploiting the pleiotropic nature of the original plant hormone, genistein, with its known therapeutic potential in a range of therapeutic indications including lysosomal storage diseases (eg San Filippo Syndrome) as well as an ability (discovered by Novogen scientists) to promote the function of dysfunctional or under-performing tissue stem cells.
Alzheimer’s disease, fascioscapulohumeral dystrophy (FSHD), nemaline dystrophy and San Filippo Syndrome are 4 clinical indications currently being actively pursued.
In the case of the ATM platform, the same molecular target of Anisina in cancer cells (tropomyosin isoform Tm5NM1) has been implicated in ulcerative colitis. But beyond this disease, the structural integrity of a cell (its cytoskeleton) is becoming increasingly seen as being integral to many autoimmune disease processes beyond ulcerative colitis. Novogen believes that its world-leading research into the biology of tropomyosin and the ability to target this protein with designer drugs, opens up a major new drug development opportunity
Sorry if I seem to have gone on about this but I like to dot the I's and cross the T's and this certainly does that.
